Century Therapeutics, Inc. (IPSC) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
IPSC Revenue Growth
IPSC Revenue Analysis (2019–2025)
As of May 8, 2026, Century Therapeutics, Inc. (IPSC) generated trailing twelve-month (TTM) revenue of $109.2 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, IPSC's historical revenue data shows a 3-year CAGR of +175.9%. The company achieved its highest annual revenue of $109.2 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including FATE (-51.2% YoY), NKTR (-43.9% YoY), and IOVA (+34.3% YoY), IPSC has underperformed the peer group in terms of revenue growth. Compare IPSC vs FATE →
IPSC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IPSCCurrent | $109M | -100.0% | - | -15.8% | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% | |
 IOVA | $264M | +34.3% | - | -153.1% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% |
IPSC Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $109.2M | +1556.8% | $0 | - | $-17,269,000 | -15.8% |
| 2024 | $6.6M | +194.8% | $6.6M | 100.0% | $-138,137,000 | -2096.5% |
| 2023 | $2.2M | -57.0% | $2.2M | 100.0% | $-146,546,000 | -6556.9% |
| 2022 | $5.2M | - | $5.2M | 100.0% | $-133,831,000 | -2574.2% |
| 2021 | $0 | - | $-4,582,000 | - | $-94,883,000 | - |
| 2020 | $0 | - | $-1,754,000 | - | $-49,176,000 | - |
| 2019 | $0 | - | $-249,000 | - | $-20,033,000 | - |
See IPSC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IPSC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IPSC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIPSC — Frequently Asked Questions
Quick answers to the most common questions about buying IPSC stock.
Is IPSC's revenue growth accelerating or slowing?
IPSC revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $109M. This reverses the prior growth trend.
What is IPSC's long-term revenue growth rate?
Century Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is IPSC's revenue distributed by segment?
IPSC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.